Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TNX 1800

Next Previous
Drug Profile

TNX 1800

Alternative Names: Coronavirus vaccine - Tonix Pharmaceuticals; COVID-19 vaccine - Tonix Pharmaceuticals; Live modified horsepox virus vaccine - Tonix Pharmaceuticals; TNX-1800

Latest Information Update: 08 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tonix Pharmaceuticals Holding Corp
  • Class COVID-19 vaccines; Recombinant proteins; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 01 Apr 2024 Preclinical development in COVID-2019 infections(Prevention) is ongoing in USA (Topical) (Tonix Pharmaceuticals pipeline, April 2024)
  • 28 Mar 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Topical)
  • 02 Nov 2023 Tonix Pharmaceuticals Holding Corp in collaboration with National Institute of Allergy and Infectious Diseases plans a phase I trial in COVID-2019 infections (Prevention) (Topical), in the second half of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top